Efficacy of Gefapixant in the Treatment of Chronic Cough
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Lancet 2022 Mar 05;399(10328)909-923, LP McGarvey, SS Birring, AH Morice, PV Dicpinigaitis, ID Pavord, J Schelfhout, AM Nguyen, Q Li, A Tzontcheva, B Iskold, SA Green, C Rosa, DR Muccino, JA SmithFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.